
Nephrocare Health Services Ltd IPO Price Range is ₹438 - ₹460, with a minimum investment of ₹14,720 for 32 shares per lot.
Minimum Investment
₹14,720
/ 32 shares
IPO Status
Pre-application open
Price Band
₹438 - ₹460
Bidding Dates
Dec 10, 2025 - Dec 12, 2025
Issue Size
₹871.05 Cr
Lot Size
32 shares
Min Investment
₹14,720
Listing Exchange
NSE
Indias and Asias largest dialysis chain with leadership across our markets.
Scale coupled with asset-light model driving cost efficiencies and operational excellence.
Driving clinical excellence and quality through protocols and advanced technology.
Organic growth augmented by proven track record of acquisitions and integration in India and internationally.
Patient-centric leadership and seasoned management team backed by marquee investors.
Driving sustainable dialysis leadership with environmental, social and governance measures.
Track record of sustainable growth, profitability and return.
Our Company and Subsidiaries are involved in certain legal and regulatory proceedings. Any adversedecision in such proceedings may have an adverse effect on our business, financial condition, cash flowsand results of operations.
Our business depends on the strength of our brand and reputation. Failure to maintain and enhance ourbrand and reputation, and any negative publicity and allegations in the media against us, even if untrue,may adversely affect the brand, reputation and trust in, our services, which could result in a materialadverse impact on our business, financial condition, results of operations and prospects.
We rely on our in-house and third-party information technology systems in providing our services andmanaging our operations, and any disruption to such systems or networks could adversely affect ourbusiness operations, reputation and financial performance.
We derive a substantial portion of our revenues from clinics located in southern region of India, and anyloss of business in such regions could have an adverse effect on our business, results of operations andfinancial condition.
We face competition from hospitals and other dialysis service providers. Any adverse effects on ourcompetitive position could result in a decline in our business, revenues, profitability and market share.
The dialysis services market is subject to certain threats and challenges, which if materialize, mayadversely affect our business, results of operations, financial condition and cash flows.
Our business depends on the demand for dialysis services, which is affected by patient preferences,economic condition, social factors, disposable income and increasing general health awareness of Indiasgeneral population, which could decline due to a variety of factors.
The healthcare reimbursement framework in the Philippines is subject to periodic revisions, which mayadversely affect our business, results of operations, financial condition and cash flows.
Annual indexation under our PPP dialysis contract in Uzbekistan may not fully mitigate inflationary andcost escalation risks, thereby adversely affecting our business, results of operations, financial conditionand cash flows.
We are required to furnish bank guarantees and letters of credit as part of our business operations. Ourinability to arrange such guarantees or the invocation of such guarantees may adversely affect our cashflows and financial condition.